NANOVIRICIDES, INC.

NNVC · NYSE · SIC 2834: Pharmaceutical Preparations
249
SEC Filings

Business Summary

NanoViricides, Inc. is a clinical-stage biopharmaceutical company developing antiviral drugs called nanoviricides, based on nanomedicine platform technology. Its lead drug candidate, NV-387, has completed Phase Ia/Ib human clinical safety and tolerability trials and is ready for Phase II efficacy trials. NV-387 targets COVID-19, RSV, Influenza, Orthopoxvirus (Smallpox/MPox), and Measles. The company has no revenues or commercialized products and operates from Shelton, Connecticut.

Next Earnings

Q2 FY2026 — expected 2026-09-21

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionNNVCdiscussed_in_filing Cybersecurity
topic_mentionNNVCdiscussed_in_filing Trusted Computing
topic_mentionNNVCdiscussed_in_filing Blockchain & Crypto
topic_mentionNNVCdiscussed_in_filing Regulation
topic_mentionNNVCdiscussed_in_filing Healthcare & Bio
topic_mentionNNVCdiscussed_in_filing Platform & Ecosystem
topic_mentionNNVCdiscussed_in_filing Sovereign & Government
topic_mentionNNVCdiscussed_in_filing Cybersecurity
topic_mentionNNVCdiscussed_in_filing Trusted Computing
topic_mentionNNVCdiscussed_in_filing Blockchain & Crypto
topic_mentionNNVCdiscussed_in_filing Regulation
topic_mentionNNVCdiscussed_in_filing Healthcare & Bio
topic_mentionNNVCdiscussed_in_filing Platform & Ecosystem
topic_mentionNNVCdiscussed_in_filing Sovereign & Government
topic_mentionNNVCdiscussed_in_filing Cybersecurity
topic_mentionNNVCdiscussed_in_filing Trusted Computing
topic_mentionNNVCdiscussed_in_filing Blockchain & Crypto
topic_mentionNNVCdiscussed_in_filing Regulation
topic_mentionNNVCdiscussed_in_filing Healthcare & Bio
topic_mentionNNVCdiscussed_in_filing Platform & Ecosystem

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2025-09-292025-06-300001104659-25-094527EDGAR87K words
2024-09-272024-06-300001410578-24-001650EDGAR—
2023-10-132023-06-300001410578-23-002146EDGAR—
2022-10-132022-06-300001410578-22-002878EDGAR—
2021-10-122021-06-300001104659-21-125343EDGAR—
2020-10-132020-06-300001104659-20-114577EDGAR—
2019-08-232019-06-300001144204-19-041547EDGAR—
2018-10-122018-06-300001144204-18-053665EDGAR—
2017-09-282017-06-300001144204-17-050412EDGAR—
2016-09-162016-06-300001144204-16-124276EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2026-02-172025-12-310001104659-26-016476EDGAR35K words
2025-11-142025-09-300001104659-25-112608EDGAR—
2025-05-152025-03-310001410578-25-001336EDGAR—
2025-02-142024-12-310001410578-25-000140EDGAR—
2024-11-142024-09-300001410578-24-001991EDGAR—
2024-05-152024-03-310001410578-24-000843EDGAR—
2024-02-142023-12-310001410578-24-000048EDGAR—
2023-11-142023-09-300001410578-23-002484EDGAR—
2023-05-152023-03-310001410578-23-001235EDGAR—
2023-02-142022-12-310001410578-23-000129EDGAR—
2022-11-142022-09-300001410578-22-003398EDGAR—
2022-05-162022-03-310001410578-22-001688EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2025-11-260001104659-25-116457EDGAR1K words
2025-11-140001104659-25-112644EDGAR—
2025-10-010001104659-25-095676EDGAR—
2024-12-120001104659-24-128066EDGAR—
2024-08-090001104659-24-087828EDGAR—
2024-04-050001104659-24-044367EDGAR—
2024-02-160001104659-24-024973EDGAR—
2024-01-190001104659-24-005254EDGAR—
2023-11-070001104659-23-114862EDGAR—
2023-09-010001104659-23-097802EDGAR—

249 total filings indexed. 217 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

antiviral-therapeutics nanomedicine infectious-disease-treatment clinical-stage-drug-development ind-(investigational-new-drug-application) fda-nda-(new-drug-application) ema-(european-medicines-agency)-approval-process

Company Identity

CIK0001379006
TickerNNVC
ExchangeNYSE
SIC2834: Pharmaceutical Preparations
IncorporatedDE
HeadquartersShelton, Connecticut

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: e0b59eb6793ffababd9610b87290a7ca76668cbc2a2153a0b6f9ef0ad1066935
parent: 3d1736880fce402f223b79eb9d64375f7f8ac2afe8c3770e6d6285131ae09190
content hash: 8e570210d358fe910e521d959d0e4d4d65d29eb1bab81083f700c17267a8335a
signed: 2026-04-13T04:46:32.813Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf